Vaxart launches sentinel cohort for Phase 2b trial of oral COVID-19 vaccine in the US

Vaxart, Inc. has started the sentinel cohort of its Phase 2b clinical trial for an oral COVID-19 vaccine. This part of the study will involve 400 participants, comparing Vaxart's vaccine to an approved mRNA vaccine. The trial is funded by the U.S. government's Project NextGen, which aims to develop innovative COVID-19 solutions. After reviewing initial safety data, the trial will expand to include 10,000 participants. This study marks a significant step for Vaxart, which is known for its oral vaccine technology. The trial will assess the vaccine's safety, efficacy, and immune response in adults previously vaccinated against COVID-19.